How have the shares performed?
Petros Pharmaceuticals Inc. (PTPI) saw an uptrend of 18.39% in the recent trading with $3.67 being its most recent. The current price level -38.42% lower than the highest price of $5.96 marked by the stock while trading over the past 52-weeks, whereas it is 103.89% higher than the lowest price of $1.80 the company dropped to over past 52-weeks. The latest news story on PTPI appeared in PR Newswire under the title “Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021” on Jun-02-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -13.44% below one month high and is +30.14% above of the lowest during that time. Looking into the simple moving average, Petros Pharmaceuticals Inc. (PTPI)’s stock stands at a SMA-50 of $3.17 while that of 5-day is reading $3.28.
Petros Pharmaceuticals Inc. Earnings – What Happened With PTPI
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $4.08 billion.
PTPI – Petros Pharmaceuticals Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 9.75 million. PTPI does have institutional investors; and they hold 9.70% of the stock.
Petros Pharmaceuticals Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, PTPI declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Mar 30, 2021, NorthRock Partners, LLC was the top most holder in Petros Pharmaceuticals Inc. (NASDAQ:PTPI) with an ownership of 0.34 million shares of the company or 3.44% of the stake worth $1.26 million. The filing also reveals Renaissance Technologies, LLC as the second largest holder in the company with a control over 1.89% of the outstanding shares. Its stake is worth $0.69 million for having 0.19 million shares in hand.
Vanguard Group, Inc. (The) also came holding a key position in the company during the recent quarter and it now holds 0.91% of the outstanding shares. With this there are now 21 institutions which have possession in PTPI’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Petros Pharmaceuticals Inc. was 0.62 while posting a debt to equity ratio of 0.24. The count was 3.04 for long-term debt to equity ratio.